Projects per year
Organization profile
Organisation profile
The research proup HEIM is part of the departement IMMI and centers its activity on the biology and treatment of haematological diseases. This activity is spread over the departments of Clinical Haematology and Stem Cell Transplantation (AZ VUB), Clinical Laboratory of Haematology and Immunology (AZ VUB), Blood Transfusion Centre Jette (Red Cross) and the basic research laboratory HEIM at the faculty of medicine. Following specific subjects are under study: 1. Biology of multiple myeloma and related diseases; 2. Molecular and phenotypic follow-up of B cell malignancies during therapy; 3. Stem cell processing and clinical transplantation; 4. Analysis of phenotype of haemopoietic stem cells in health and disease; 5. Homing of mesenchymal stem cell in bone marrow 5. MHC dysregulation in haematological malignancies; 6. Molecular analysis of antithrombine deficiency.
Fingerprint
Dive into the research topics where Hematology is active. These topic labels come from the works of this organisation's members. Together they form a unique fingerprint.
Network
Recent external collaboration on country level. Dive into details by clicking on the dots or
Profiles
-
Marleen Bakkus
- UZBrussel
- Vrije Universiteit Brussel
- Clinical Biology - UZB Researcher
- Hematology
Person: Researcher
-
Veerle Beckers
- UZBrussel
- Vrije Universiteit Brussel
- Hematology
- Hematology - UZB Physician
Person: Researcher, Physician
-
Ann De Becker
- UZBrussel
- Vrije Universiteit Brussel
- Hematology
- Faculty of Medicine and Pharmacy
- Hematology - UZB Physician
Person: Researcher, PhD, Physician
-
Nathan De Beule
- UZBrussel
- Vrije Universiteit Brussel
- Clinical sciences - Academic
- Hematology - UZB Physician
- Hematology
Person: Researcher, Physician
-
Wouter De Brouwer
- UZBrussel
- Vrije Universiteit Brussel
- Hematology
- Basic (bio-) Medical Sciences - Academic
- Hematology - UZB Physician
- Faculty of Medicine and Pharmacy
Person: Researcher, Physician, PhD, Advanced Master's Programme
Projects
-
OZR3740: Bilateral cooperation within the framework of a joint doctoral project: benchfee for joint PhD VUB - KU Leuven, DE COSTER Michiel
22/10/20 → 21/10/24
Project: Fundamental
-
FWOTM1002: Development of innovative NANObody-based therapies to eradicate REsidual disease in Multiple Myeloma (acronym: NANOREMM)
1/10/20 → 30/09/23
Project: Fundamental
-
FWOTM900: Modulating epigenetic mechanisms to enhance cancer immunotherapy.
Breckpot, K., De Beck, L. & Maes, K.
1/10/18 → 30/09/22
Project: Fundamental
-
OZR3286: Bilateral cooperation within the framework of a joint doctoral project: Bench Fee for Joint PhD VUB-UGent, Vlummens Philip
13/02/18 → 31/12/22
Project: Fundamental
Research output
-
Antithrombin p.Thr147Ala: The First Founder Mutation in People of African Origin Responsible for Inherited Antithrombin Deficiency
Orlando, C., de la Morena-Barrio, B., Pareyn, I., Vanhoorelbeke, K., Martínez-Martínez, I., Vicente, V., Corral, J., Jochmans, K. & de la Morena-Barrio, M. E., 1 Feb 2021, In : Thrombosis and Haemostasis. 121, 2, p. 182-191 10 p.Research output: Contribution to journal › Article
1 Citation (Scopus) -
A pilot study on the impact of congenital thrombophilia in COVID-19
de la Morena-Barrio, M. E., Bravo-Pérez, C., de la Morena-Barrio, B., Orlando, C., Cifuentes, R., Padilla, J., Miñano, A., Herrero, S., Marcellini, S., Revilla, N., Bernal, E., Gómez-Verdú, J. M., Jochmans, K., Herranz, M. T., Vicente, V., Corral, J. & Lozano, M. L., May 2021, In : European Journal of Clinical Investigation. 51, 5, 8 p., e13546.Research output: Contribution to journal › Article
1 Citation (Scopus) -
Combining dual G9a/DNMTs epigenetic inhibition and immunotherapy to treat metastatic melanoma
De Beck, L., Awad, R. M., De Vlaeminck, Y., Basso, V., Casares, N., Verhulst, S., San José-Enériz, E., De Ridder, K., Goyvaerts, C., Maes, K., Vanderkerken, K., Agirre, X., Prosper, F., Lasarte, J. J., Mondino, A. & Breckpot, K., 11 Feb 2021.Research output: Unpublished contribution to conference › Other
-
Dialyzer Performance During Hemodialysis Without Systemic Anticoagulation Using a Heparin-Grafted Dialyzer Combined With a Citrate-Enriched Dialysate: Results of the Randomized Crossover Noninferiority EVOCIT Study
François, K., De Clerck, D., Tonnelier, A., Cambier, M-L., Orlando, C., Jochmans, K., Cools, W. & Wissing, K. M., 30 Apr 2021, In : American Journal of Kidney Diseases.Research output: Contribution to journal › Article
-
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations
Rosiñol, L., Beksac, M., Zamagni, E., Van de Donk, N. W. C. J., Anderson, K. C., Badros, A., Caers, J., Cavo, M., Dimopoulos, M-A., Dispenzieri, A., Einsele, H., Engelhardt, M., Fernández de Larrea, C., Gahrton, G., Gay, F., Hájek, R., Hungria, V., Jurczyszyn, A., Kröger, N., Kyle, R. A. & 18 others, , 2021, In : British Journal of Haematology.Research output: Contribution to journal › Article
Activities
-
LSM PHD DAY
Margo Willems (Chair), Wout De Mey (Chair), Axelle Cooreman (Organiser), Michiel De Coster (Organiser), Hamide Yildirim (Organiser), Catharina Muylaert (Organiser)31 Mar 2021Activity: Participating in or organising an event › Participation in workshop, seminar
-
LSM PhD day 2021
Michiel De Coster (Organiser)30 Mar 2021Activity: Participating in or organising an event › Participating in or organizing a school event
-
Targeting of pyrroline-5-carboxylate reductase (PYCR) reduces drug resistance in multiple myeloma in vitro.
Inge Oudaert (Speaker), Eline Menu (Contributor), Kim De Veirman (Contributor)29 Jan 2021 → 30 Jan 2021Activity: Talk or presentation › Talk or presentation at a conference
-
AXL: A potential therapeutic target to eliminate cancer cells and improve chemotherapeutic responses in different hematological cancers (BHS Gam 2020)
Kim De Veirman (Presenter)14 Feb 2020 → 16 Feb 2020Activity: Talk or presentation › Talk or presentation at a conference
-
AXL: A potential therapeutic target to eliminate cancer cells and improve chemotherapeutic responses in different hematological cancers (ORC dag 2020)
Kim De Veirman (Speaker)16 Oct 2020Activity: Talk or presentation › Talk or presentation at a conference